Poland· PL-100510030
Lumykras
A sotorasib product containing sotorasibum, registered in Poland by Amgen Europe B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sotorasib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX73 (sotorasib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Sotorasib · ATC L01XX73
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Sotorasibum
- Manufacturer
- Amgen Europe B.V.
- Country
- Poland (PL)
- ATC code
- L01XX73
- ATC class
- Sotorasib
- Defined daily dose
- 0.96 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08715131029081
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sotorasib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandLUMYKRASAmgen Europe B.V.
- CzechiaLUMYKRASAmgen Europe B.V., Breda
- SpainLUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAmgen Europe B.V.
- IrelandLUMYKRAS 240 mg film-coated tabletsAmgen Europe B.V.,
- IcelandLumykrasAmgen Europe B.V.*
- NetherlandsLumykras 240 mg, filmomhulde tablettenAmgen Europe B.V.
- BelgiumLumykras 240 mgAmgen Europe
- SwedenLUMYKRAS 240 mg Filmdragerad tablettAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Lumykras
- Norway · Lumykras
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/99b8b08d-f69a-4f44-8fe6-6ffd6bb5b42f GET /v1/drugs/99b8b08d-f69a-4f44-8fe6-6ffd6bb5b42f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "240 mg",
"packaging": "08715131029081 ¦ Rpz ¦ EU/1/21/1603/004 ¦ 159512\n120 tabl. w blistrze perforowanym",
"substance": "Sotorasibum 240 mg",
"common_name": "Sotorasibum",
"pl_product_id": "100510030",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sotorasib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.